Published in Trans Am Clin Climatol Assoc on January 01, 2007
Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation (2009) 0.94
Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/- IL-2Rγ-/- mice: a promising model for studying human disease. Arthritis Rheum (2011) 0.93
Tracing the molecular pathogenesis of antiphospholipid syndrome. J Clin Invest (2008) 0.78
Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp Ther Med (2012) 0.78
Pathophysiology of the antiphospholipid antibody syndrome. Auto Immun Highlights (2011) 0.76
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum (1999) 7.67
The antiphospholipid syndrome. N Engl J Med (2002) 5.42
A critical role for murine complement regulator crry in fetomaternal tolerance. Science (2000) 3.27
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med (1996) 2.67
Control of the complement system. Adv Immunol (1996) 2.43
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 2.39
Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem (1999) 2.33
Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem (1989) 2.20
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med (2002) 2.09
Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol (2003) 1.89
Membrane proteins that protect against complement lysis. Springer Semin Immunopathol (1994) 1.83
Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med (1995) 1.74
A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol (2001) 1.73
Complement receptors and phagocytosis. Curr Opin Immunol (1991) 1.70
Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol (2004) 1.61
Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med (1994) 1.61
Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum (2000) 1.49
A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int (2003) 1.41
Seeking wisdom in innate immunity. Nature (1997) 1.37
Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol (1998) 1.32
Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol (1991) 1.28
Mannan-binding lectin--a soluble pattern recognition molecule. Mol Immunol (2004) 1.28
Management of the obstetric antiphospholipid syndrome. Arthritis Rheum (2004) 1.23
Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol (1995) 1.23
Structure and function of C3a anaphylatoxin. Curr Top Microbiol Immunol (1990) 1.19
A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J Immunol (2000) 1.15
Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol (1992) 1.09
The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am J Reprod Immunol (1998) 1.08
Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol (1998) 1.06
Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends Mol Med (2004) 1.02
Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum (1996) 1.01
Initiation of complement activation following oxidative stress. In vitro and in vivo observations. Mol Immunol (2004) 1.01
Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol (1993) 0.99
Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clin Immunol Immunopathol (1995) 0.94
Complement component deposition in uteroplacental (spiral) arteries in normal human pregnancy. J Reprod Immunol (1987) 0.92
Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury. Curr Dir Autoimmun (2004) 0.90
Immunofluorescent studies of the uteroplacental arteries in normal pregnancy. Br J Obstet Gynaecol (1981) 0.89
The effects of complement activation on platelets. Curr Top Microbiol Immunol (1992) 0.87
Complement: a critical test of its biological importance. Immunol Rev (2000) 0.82
Autoimmune disease as a cause of reproductive failure. Clin Lab Med (2003) 0.81
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med (2002) 2.09
Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest (2010) 1.77
A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol (2005) 1.67
Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood (2007) 1.49
Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum (2005) 1.26
Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice. Am J Pathol (2011) 1.25
Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest (2008) 1.23
TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol (2005) 1.23
Role of complement component C1q in the onset of preeclampsia in mice. Hypertension (2011) 1.22
A new mouse model to explore therapies for preeclampsia. PLoS One (2010) 1.21
Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol (2004) 1.20
Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood (2009) 1.02
Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood (2009) 1.01
An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol (2010) 0.98
Cervical remodeling/ripening at term and preterm delivery: the same mechanism initiated by different mediators and different effector cells. PLoS One (2011) 0.97
The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol (2007) 0.97
Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol (2011) 0.96
The role of complement in the antiphospholipid syndrome. Curr Dir Autoimmun (2004) 0.94
Complement inhibition and statins prevent fetal brain cortical abnormalities in a mouse model of preterm birth. Biochim Biophys Acta (2013) 0.93
Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol (2007) 0.93
Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci (2005) 0.86
Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Exp Med (2007) 0.84
Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension (2014) 0.80
Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest (2016) 0.80
Comparison of the mechanisms responsible for cervical remodeling in preterm and term labor. J Reprod Immunol (2013) 0.79